Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.19
Views: 500
Rating:

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Prof Philippe Moreau talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the part 1 results from the CASSIOPEIA trial studying daratumumab plus bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible newly diagnosed multiple myeloma (NDMM).

He explains that the primary endpoint of the study was to compare the quality of the response after consolidation and before maintenance while also looking at overall survival, progression free survival and the rate of minimal residual disease.

Prof Moreau reports a clear demonstration across 1000 randomised patients that the addition of daratumumab is increasing the quality of the response and also the minimal residual disease negativity rate which translates to an improved progression free survival.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation